However, in December 2004 the United States the 14-member Food and Drug Administration (FDA) advisory committee, plus voting consultants, for Reproductive Health Drugs unanimously rejected Procter and Gamble's fast-track request for Intrinsa citing concerns about off-label use . In Canada, post-menopausal women have been able to obtain government-approved testosterone treatment since 2002. In Australia, post-menopausal women can use Organon testosterone implants which have to be surgically inserted and last from three to six months. 
Like other AAS, boldenone is an agonist of the androgen receptor (AR).  The activity of boldenone is mainly anabolic , with a low androgenic potency. Boldenone will increase nitrogen retention, protein synthesis, increases appetite and stimulates the release of erythropoietin in the kidneys.  Boldenone was synthesized in an attempt to create a long-acting injectable metandienone , for androgen deficiency disorders. Boldenone acts similar to metandienone with fewer adverse androgenic effects. [ medical citation needed ] Although commonly compared to nandrolone , boldenone lacks progesterone receptor interaction and associated progestogenic side effects.